Abivax S.A.
0RA9.L
Get informed when a big investor buys or sells
+ FollowMarket Cap$10.21B
Close$
$6.97
90.9% downside
Current Fair Value
90.9% downsideOvervalued by 90.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $10.21 Billion |
|---|---|
| Enterprise Value | $9.82 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-4.83 |
| Beta | -0.21 |
| Outstanding Shares | 69,527,315 |
Return
| Return on Equity | -133.12% |
|---|---|
| Return on Assets | -105.49% |
| Return on Invested Capital | -104.99% |
Valuation & Multiples
| P/E Ratio | -16.77 |
|---|---|
| PEG | -101.53 |
| Price to Sales | - |
| Price to Book Ratio | 15.32 |
| Enterprise Value to Revenue | 4902.93 |
| Enterprise Value to EBIT | -23.95 |
| Enterprise Value to Net Income | -21 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
September 21, 2026
EPS Estimate
$-0.80
Average shareholder expectationRevenue Estimate
$697,707
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Abivax
69 employees
CEO: Marc de Garidel Based in Paris, France, ABIVAX Société Anonyme is a biopharmaceutical company dedicated to the discovery and optimization of novel drug treatments. Their research and development efforts primarily target inflammatory conditions, infectio...